Targeting mTOR in cancer: renal cell is just a beginning
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Oncology
Link
http://link.springer.com/content/pdf/10.1007/s11523-010-0141-x.pdf
Reference88 articles.
1. Vezina C, Kudelski A, Sehgal SN (1975) Rapamycin (AY-22, 989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 28:721–726
2. Martel RR, Klicius J, Galet S (1977) Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol 55:48–51
3. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M et al (1987) FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 40:1249–1255
4. Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124:471–484
5. Nave BT, Ouwens M, Withers DJ, Alessi DR, Shepherd PR (1999) Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J 344:427–431
Cited by 33 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Daprodustat prevents cyclosporine-A–mediated anemia and peritubular capillary loss;Kidney International;2022-10
2. FAM65A as a novel prognostic biomarker in human tumors reveal by a pan-cancer analysis;Discover Oncology;2021-12
3. Sirolimus use improves cancer-free survival following transplantation: A single center 12-year analysis;Transplantation Reports;2020-06
4. Understanding the benefits and challenges of first‐line cyclin‐dependent kinases 4 and 6 inhibitors in advanced breast cancer among postmenopausal women;The Breast Journal;2019-11-10
5. The circular RNA hsa-circ-0072309 plays anti-tumour roles by sponging miR-100 through the deactivation of PI3K/AKT and mTOR pathways in the renal carcinoma cell lines;Artificial Cells, Nanomedicine, and Biotechnology;2019-08-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3